UNIVERSITY OF FLORIDA RESEARCH FOUNDATION; INCORPORATED
发明人:
YAIMA L. LIGHTFOOT,BIKASH SAHAY,MANSOUR MOHAMADZADEH
申请号：
US16804020
公开号：
US20200207814A1
申请日:
2020.02.28
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.
